Johnson & Johnson
JNJHealthcare
$247.55
-0.35%
Price History (1 Year)
Market Cap
$596.6B
P/E Ratio
22.4x
P/B Ratio
6.18x
EV/EBITDA
13.3x
ROE
32.9%
FCF Yield
3.9%
Div. Yield
2.10%
DCF Value
$318.19
Undervalued vs DCF
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025-12-28 | $24.56B | $5.12B | $2.10 |
| 2025-09-28 | $23.99B | $5.15B | $2.14 |
| 2025-06-29 | $23.74B | $5.54B | $2.29 |
| 2025-03-30 | $21.89B | $11.00B | $4.57 |
AI Analysis
JNJ: $24B Beat and a Guidance Raise — Buy the Dip
- •JNJ's Q1 2026 revenue of $24.06B beat estimates by $450M, growing 9.9% YoY despite a 61.7% decline in Stelara sales from biosimilar competition.
- •Management raised 2026 guidance to $100.8B in sales and $11.55 adjusted EPS, signaling the portfolio can grow through the biosimilar cliff.
- •The OTTAVA robotic surgical system FDA application is advancing and represents JNJ's most significant MedTech catalyst, targeting a $7B+ market.
Read full analysis →
Healthcare Peers
Data provided by Financial Modeling Prep. AI analysis generated by Claude. This is not financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.